Biotech entity
Of the tracked stories, 2 of 3 also mention HC Wainwright, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 4 for the same window. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category.
Last mentioned: Aug 31, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention HC Wainwright, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 4 for the same window. Coverage clusters in pharma, which accounts for 2 of those 3, with the remainder spread across 1 other category. The 5 average consequence score is below the beat benchmark of 6.1 in the same window. Across a 33-day span, the pace is roughly 0.6 stories per week. This profile follows 3 Biotech stories mentioning UBS Group across the period from July 11, 2026 to August 12, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 204 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering UBS Group. Shared-story counts are live from our verified record — not editorial picks.
Schikan sells 30,712 shares
Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
HC Wainwright reiterates buy rating
HC Wainwright reaffirmed its buy rating on Pharvaris shares.
UBS sets $74 price target
UBS Group issued a research note with a $74 price objective on Pharvaris.
Q1 earnings beat
Pharvaris reported Q1 EPS of -$0.70, beating the consensus estimate of -$0.82.
Weiss Ratings issues sell (d-) rating
Weiss Ratings reaffirmed a sell rating on Pharvaris shares, citing financial risks.
Wedbush raises price target to $42
Wedbush lifted its price target on Pharvaris from $41 to $42 with an outperform rating.
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Source: The Lincolnian Online · Bbns
UBS Group is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
